Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry Sells 3,259 Shares

Artivion, Inc. (NYSE:AORT) CFO Lance A. Berry sold 3,259 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $89,003.29. Following the completion of the sale, the chief financial officer now owns 75,805 shares of the company’s stock, valued at approximately $2,070,234.55. This trade represents a 4.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Artivion Stock Down 0.1 %

Artivion stock opened at $25.34 on Friday. The firm has a market cap of $1.06 billion, a PE ratio of -1,267.00 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The firm’s 50 day moving average price is $29.58 and its two-hundred day moving average price is $27.80. Artivion, Inc. has a twelve month low of $18.38 and a twelve month high of $32.33.

Artivion (NYSE:AORT) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. On average, research analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC increased its stake in shares of Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares during the last quarter. Quarry LP increased its stake in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the last quarter. R Squared Ltd acquired a new position in shares of Artivion during the 4th quarter worth $39,000. Arcadia Investment Management Corp MI acquired a new position in shares of Artivion during the 4th quarter worth $43,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion during the 4th quarter worth $64,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Oppenheimer upped their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Needham & Company LLC dropped their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Stifel Nicolaus dropped their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.